Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND FL: Lisocabtagene maraleucel in relapsed or refractory indolent B-cell non-Hodgkin lymphoma (Japan cohort)
jRCT1080225154Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and low-grade B-cell lymphoma, sponsored by Bristol Myers Squibb. Started Apr 2020; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)low-grade B-cell lymphoma
Beyond the preview
Go deeper on jRCT1080225154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225154.